News

Foamix now has a total of 25 issued US Patents, 61 issued worldwide and 126 patents pending. These new patents, which were issued between August 2013 and January

The approval makes CYRAMZA, the first FDA-approved treatment for patients with metastatic gastric cancer. Lilly Oncology senior vice president of product development and medical affairs Richard Gaynor said

CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. This agreement allows Alcresta to accelerate the development of its nutrition technology and advance

Pursuant to the terms of the research collaboration agreement, NanoSmart Pharmaceuticals and NanoValent Pharmaceuticals will explore the feasibility of jointly developing an anti-nuclear antibody (ANA)-conjugated liposomal doxorubicin nanoparticle

The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s novel, non-cytotoxic, anti-tumor therapy. The so called true human antibody therapy was reported

Volasertib is an investigational compound that inhibits enzymes called Polo-like kinase. Currently, the drug is being assessed in a Phase III clinical trial for the treatment of patients

MultiCorp International CEO Paul D. Lisenby noted that the company is extremely excited to have such a qualified and experienced group to assist the company in mapping out

Under the licensing agreement entered into on 6 March 2008, Amgen was granted exclusive rights to develop and commercialize Kyowa Hakko Kirin’s humanized monoclonal antibody mogamulizumab in all

Coldstream hosted FDA authorities from 8 April – 17 April 2014, at its manufacturing facility in Lexington. The site audit reviewed quality systems to ensure compliance with current